CLRB Cellectar Biosciences, Inc.
P/E
--
Forward P/E
--
Price/Sales
348.47
Beta
0.577
Div Yield
--
Market Cap
--
Company Analysis
Latest News
Cellectar Biosciences meets third quarter 2026 earnings expectations while advancing 1H 2027 NDA plans
Cellectar Biosciences reported a third quarter 2026 net loss of $8.0 million, matching analyst earnings per share estimates. The company is prioritizing its...
Cellectar Biosciences Inc Q3 2026 Earnings Preview: What Analysts Expect on November 10, 2026
Cellectar Biosciences is expected to report a Q3 2026 loss of $0.46 per share on nil revenue, with its $1.22 share price trading significantly below the $11.50...